Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines

HUI JUN LIM, XIAOCHUN WANG, PHILIP CROWE, DAVID GOLDSTEIN and JIA-LIN YANG

Sarcoma and Nano-oncology Group, Adult Cancer Program, Lowy Cancer Research Centre, Department of Medical Oncology and Surgery, Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, NSW, Australia

Abstract. Background/Aim: Sarcoma carries a poor prognosis prompting the need for targeted therapies aimed at deregulated signaling pathways. These include the PI3K/Akt/mTOR pathway commonly up-regulated in malignancies attributed to loss of PTEN expression. However, PTEN status and activation state of PI3K/Akt/mTOR pathway have not been comprehensively studied in sarcoma. The aims of this study were to characterise PTEN and Akt expression in a panel of sarcoma cell lines and then to examine mTOR inhibition using ridaforolimus. Materials and Methods: PTEN genomic expression was analyzed using Sanger sequencing. PTEN, total Akt (tAkt) and phosphorylated Akt (pAkt) expression were quantified with western blot analysis. Antiproliferative effects of treatment regimens were designed using Chou & Talalay's isobologram and determined with crystal violet assay. Results: Four cell lines had wild-type PTEN (exons 2 to 8), with normal protein expression. The GCT cell line had a missense mutation in exon 6 (C>T), associated with loss of PTEN protein expression. Increased pAkt expression was found in all cell lines following epidermal growth factor (EGF) stimulation, indicating that wild-type PTEN expression in four cell lines did not inhibit constitutive activation of PI3K/Akt/mTOR pathway. Nonetheless, all cell lines demonstrated sensitivity to ridaforolimus within a clinically relevant dose-range (half-maximal inhibitory concentration (IC50)=0.7-10 nM). Conclusion: PTEN mutation is rare in sarcoma cell lines and constitutive activation of PI3K/Akt/mTOR is independent of PTEN status.

Targeted inhibition with ridaforolimus monotherapy is a promising avenue to further investigate in sarcoma treatment. Sarcomas are a heterogeneous group of mesenchymal malignancies with more than 70 different subtypes (1, 2). Despite advances in its classification and pathogenesis, cytotoxic chemotherapy remains the standard-of-care for most sarcomas where the overall 5-year survival rate is 50% (3). In addition to their poor prognosis, chemotherapeutic regimens are associated with significant toxicity (4). There remains an urgent need for novel targeted therapies to improve clinical outcomes and tolerability in sarcoma treatment.

To develop effective targeted therapies, several key signaling pathways have attracted interest over the past decade and have been identified as potential treatment targets in sarcoma. These include epidermal growth factor receptor (EGFR) and its downstream signaling pathways, including the PI3K/AKT/mTOR cascade (5, 6). EGFR is commonly overexpressed in sarcoma and is an independent prognostic indicator of disease progression and overall survival (7, 8). In addition, its downstream pathways are constitutively activated in tumourigenesis, providing continuous signal transduction leading to increased cell growth and division (9-11). Notably, aberrant activation of PI3K/AKT/mTOR signaling is commonly attributed to phosphatase and tensin homologue (PTEN) dysfunction, which is an essential tumour suppressor gene that acts as a central negative regulator of the pathway (12, 13). Although PTEN dysfunction and constitutive activation of the PI3K/Akt/mTOR pathway have been well-established in epithelial and haematological cancers, limited studies are available in sarcoma (14, 15). Given their vital roles in oncogenesis, there is a strong basis for further examination of PTEN expression and activation state of PI3K/Akt/mTOR pathway in sarcoma. Moreover, mTOR inhibition is a potential approach to impede constitutive activation of PI3K/Akt/mTOR pathway. Hence, the aims of this study are to characterise the genomic status and protein expression of PTEN, in conjunction with Akt protein expression, in a panel of sarcoma cell lines. In addition, the growth inhibitory effects of ridaforolimus (mTOR inhibitor) will be determined.

This article is freely accessible online.

Correspondence to: Jia-Lin Yang, Lowy Cancer Research Centre, Room 209, Faculty of Medicine, UNSW, Sydney, NSW 2052, Australia. Tel: +61 293859390, Fax: +61 293851510, e-mail: j.yang@unsw.edu.au

Key Words: Sarcoma, PI3K/PTEN/Akt/mTOR pathway, PTEN expression, targeted therapy.

0250-7005/2016 $2.00+.40
were subsequently sent for sequencing following purification. For TBE buffer for 30 min at 100 V. High-quality PCR samples (Figure purification of PCR products, 5 μl of a 1:15 dilution of ExoSAP-IT electrophoresis on 1% agarose gel containing GelRed™ (Biotium, specificity of PCR samples were verified by agarose gel followed by a final extension at 72˚C for 10 min. The integrity and Thermocycling parameters were an initial denaturation at 94˚C for 2 min, followed by denaturation at 94˚C, annealing at 55˚C and extension at 72˚C for 30 s each and repeated for 35 cycles. This was followed by a final extension at 72˚C for 10 min. The integrity and specificity of PCR samples were verified by agarose gel electrophoresis on 1% agarose gel containing GelRed™ (Biotium, Inc., Hayward, CA, USA). The gel was electrophoresed with 0.5% TBE buffer for 30 min at 100 V. High-quality PCR samples (Figure 1) were subsequently sent for sequencing following purification. For purification of PCR products, 5 μl of a 1:15 dilution of ExoSAP-IT

### Materials and Methods

**Cell lines.** Five human sarcoma cell lines were used for this study, representing different pathological subtypes: liposarcoma (778 and 449B), fibrosarcoma (HT1080), synovial sarcoma (SW982) and malignant fibrous histiocytoma (GCT). All cell lines were purchased from American Type of Cell Culture (Manassas, VA, USA) and validated by CellBank, Australia (www.cellbankaustralia.com.au). Cell lines were maintained in RPMI 1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 2 mM L-Glutamine, 50 units/ml penicillin, 50 μg/ml streptomycin and 10% fetal bovine serum at 37˚C in 5% CO2 atmosphere and demonstrated to be free of mycoplasma contamination.

**Drug inhibitors.** Stock solutions of 10 mM for ridaforolimus (mTOR inhibitor) were prepared in dimethyl sulfoxide (DMSO) and stored in aliquots at ~−20˚C. Ridaforolimus was purchased from SelleckChem (Sydney, Australia).

**DNA extraction.** DNA was extracted from each cell line using QIAamp DNA Mini Kit (Qiagen, Valencia, CA, USA) according to manufacturer’s protocol. Concentration and purity of extracted DNA were determined using NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Roskilde, Denmark); A260/280 ratio for cell lines were between 1.80-1.90.

**Polymerase chain reaction (PCR).** PCR amplification of human-specific PTEN exons 2 to 8 was performed on C1000 Thermal Cycler (Invitrogen) using seven pairs of primers (Table I). Primer pairs were chosen in intronic regions of PTEN and designed with OligoPerfect Designer software (Invitrogen), using the reference sequence from the National Center for Biotechnology Information (NM_000314.4). PCR reactions were performed in 50 μl containing 100 ng of genomic DNA, 0.2 μM of oligonucleotide primers (Invitrogen) and 45 μl of Platinum PCR SuperMix (Invitrogen). Thermocycling parameters were an initial denaturation at 94˚C for 2 min, followed by denaturation at 94˚C, annealing at 55˚C and extension at 72˚C for 30 s each and repeated for 35 cycles. This was followed by a final extension at 72˚C for 10 min. The integrity and specificity of PCR samples were verified by agarose gel electrophoresis on 1% agarose gel containing GelRed™ (Biotium, Inc., Hayward, CA, USA). The gel was electrophoresed with 0.5% TBE buffer for 30 min at 100 V. High-quality PCR samples (Figure 1) were subsequently sent for sequencing following purification. For purification of PCR products, 5 μl of a 1:15 dilution of ExoSAP-IT

### Sequencing of PTEN gene. **Bi-directional Sanger sequencing of purified PCR products was performed at The Ramaciotti Centre for Gene Functional Analysis, University of New South Wales (Sydney, NSW, Australia) using an ABI 3730 Capillary Sequencer (Applied Biosystems, Darmstadt, Germany) and primers listed in Table I. Identified mutations were verified by bi-directional re-sequencing of original DNA sample.

**Western blot analysis.** Twenty-four hours after seeding in 6-well plates in culture medium, sarcoma cells were starved with medium containing 1% FBS for 24 h. Cells were then harvested immediately after 15 min incubation with or without 100 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich, Castle Hill, NSW, Australia) stimulation. Subsequently, protein extraction was conducted using radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with 1% protease and phosphatase inhibitor cocktails (Sigma-Aldrich, Australia). Supernatants were collected and protein concentrations determined with BCA Protein Assay (Thermo Fisher Scientific). For Western blot analysis, whole cell lysate was mixed with an SDS protein gel loading solution (Sigma-Aldrich) and heated at 95˚C for 5 min. Forty μg of protein was loaded per well alongside a molecular marker (Cell Signalling, Danvers, MA, USA) in a 4-20% Tris-glycine precast gel (Invitrogen) and electrophoresis was completed at 100 V for 60 min, before being transferred to a polyvinylidene difluoride Hybond-P membrane (Amersham, Arlington Heights, IL, USA). Membrane was blocked by incubation with 5% skim milk at room temperature for 1 h. Immunoblotting

### Table I. Primers for PCR and PTEN Sanger sequencing.

<table>
<thead>
<tr>
<th>Exon</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>PCR Product Size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>5'-TGACCACCTTTTATTACTCCAGCTA-3’</td>
<td>5'-ATCACACTGTAATGGGATCCAGGTA-3’</td>
<td>512</td>
</tr>
<tr>
<td>3</td>
<td>5'-TGAAAGACCTGGTATTTACACTCA-3’</td>
<td>5'-AAAGAACATGGAATCGCATAACA-3’</td>
<td>510</td>
</tr>
<tr>
<td>4</td>
<td>5'-AGTACCTGTATATTGGCGCATCA-3’</td>
<td>5'-ATCTCAGCCTGAAACTGCTGACT-3’</td>
<td>423</td>
</tr>
<tr>
<td>5</td>
<td>5'-CCAGTCGCAAGCTTAAATTCTC-3’</td>
<td>5'-CTCAGATCCAGGAAGAGGAAAGGA-3’</td>
<td>562</td>
</tr>
<tr>
<td>6</td>
<td>5'-CGCTACGACCCAGCTTACCAAT-3’</td>
<td>5'-GGGCTGATTTGGTGGTTATAACA-3’</td>
<td>500</td>
</tr>
<tr>
<td>7</td>
<td>5'-TTTGGCAATGACAAATAGTTGAACAGA-3’</td>
<td>5'-ATGTTACATGCCATAAGGCCCCTT-3’</td>
<td>504</td>
</tr>
<tr>
<td>8</td>
<td>5'-TGCAAAATGTTAACAATAGCGTACAGA-3’</td>
<td>5'-TTTTGACGCTGTGATACATTGGTA-3’</td>
<td>521</td>
</tr>
</tbody>
</table>

### Table II. Mean half-maximal inhibitory concentration (IC50) of ridaforolimus in sarcoma cell lines.

<table>
<thead>
<tr>
<th>Cell Line</th>
<th>Sarcoma Subtype</th>
<th>Ridaforolimus (nmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>449B</td>
<td>Liposarcoma</td>
<td>4.9</td>
</tr>
<tr>
<td>778</td>
<td>Liposarcoma</td>
<td>5.2</td>
</tr>
<tr>
<td>GCT</td>
<td>Malignant fibrous histiocytoma</td>
<td>4.8</td>
</tr>
<tr>
<td>HT1080</td>
<td>Fibrosarcoma</td>
<td>0.7</td>
</tr>
<tr>
<td>SW982</td>
<td>Synovial sarcoma</td>
<td>0.8</td>
</tr>
</tbody>
</table>

(USB, Cleveland, OH, USA) was added to each PCR sample and reactions were incubated at 37˚C followed by inactivation at 80˚C for 15 min each.

Western blot analysis. Twenty-four hours after seeding in 6-well plates in culture medium, sarcoma cells were starved with medium containing 1% FBS for 24 h. Cells were then harvested immediately after 15 min incubation with or without 100 ng/ml epidermal growth factor (EGF) (Sigma-Aldrich, Castle Hill, NSW, Australia) stimulation. Subsequently, protein extraction was conducted using radioimmunoprecipitation assay (RIPA) lysis buffer supplemented with 1% protease and phosphatase inhibitor cocktails (Sigma-Aldrich, Australia). Supernatants were collected and protein concentrations determined with BCA Protein Assay (Thermo Fisher Scientific). For Western blot analysis, whole cell lysate was mixed with an SDS protein gel loading solution (Sigma-Aldrich) and heated at 95˚C for 5 min. Forty μg of protein was loaded per well alongside a molecular marker (Cell Signalling, Danvers, MA, USA) in a 4-20% Tris-glycine precast gel (Invitrogen) and electrophoresis was completed at 100 V for 60 min, before being transferred to a polyvinylidene difluoride Hybond-P membrane (Amersham, Arlington Heights, IL, USA). Membrane was blocked by incubation with 5% skim milk at room temperature for 1 h. Immunoblotting
The concentration at which cell viability was reduced to 50% of vehicle-treated controls (half maximal inhibitory concentration \( IC_{50} \)) was determined using a sigmoidal curve fit with GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA, USA). Experimental conditions were tested in two independent experiments with the samples in three replicates each.

**Results**

**DNA sequencing of PTEN gene.** To characterise the PTEN gene, genomic sequences of exons 2 to 8 of PTEN were compared with the wild-type PTEN reference sequence obtained from the National Center for Biotechnology Information (NM_000314.4) using Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA), to screen for point mutations, insertions or deletions. Sequencing analysis revealed a homozygous point mutation (C>T) within the PTEN protein coding region of exon 6 in a soft-tissue sarcoma (STS) cell line, GCT (Figure 2). This was a missense mutation that potentially resulted in a change from proline to leucine at amino acid 204. Apart from this finding, all other cell lines held no mutations, deletions or insertions from exons 2 to 8. Duplicate experiments and sequencing were used to confirm the point mutation.

**Akt protein expression.** Total Akt (tAkt) and phosphorylated Akt (pAkt) expression in the presence or absence of EGF stimulation in sarcoma cell lines was examined to determine the activation state of PI3K/Akt/mTOR pathway. Based on densitometry analysis, tAkt and pAkt protein expression were quantified in cell lines with β-actin as loading control. In the absence of EGF, pAkt was detected in the majority of cell lines, with the exception of weak expression levels in SW982 and HT1080 (Figure 3). The expression of tAkt was present in all cell lines. Following EGF stimulation, pAkt expression levels were increased in all cell lines, while tAkt levels remained largely unchanged.
PTEN protein expression. All sarcoma cell lines were assessed for PTEN protein expression by western blot analysis, with representative samples shown in Figure 4. Based on densitometry analysis, PTEN protein expression was quantified in each of the cell lines with β-actin as the loading control. In this study, 4 cell lines displayed normal PTEN expression, whereas 1 cell line (GCT) displayed loss of PTEN expression.

In vitro antiproliferative effects of monotherapy on sarcoma cell lines. The antiproliferative effects of monotherapy on a panel of 5 sarcoma cell lines were assessed using CVA following mTOR inhibition by ridaforolimus. The classification of sensitivity to drugs are based on therapeutically relevant ridaforolimus concentrations that are able to be achieved in serum from patients under treatment; these values have similarly been used in other studies to distinguish between sensitive and resistant cell lines. These values are 10 nM for ridaforolimus (21-23). Profound sensitivity to ridaforolimus is defined as IC₅₀<1 nM, moderate sensitivity as 1 nM≤IC₅₀≤10 nM, while IC₅₀>10 nM demonstrates resistance. As shown in Figure 5, low nanomolar concentrations of ridaforolimus were found to suppress cellular proliferation in 5 cell lines examined. All cell lines were sensitive to ridaforolimus with a range of mean IC₅₀ from 0.7 nM to 5.2 nM (Table II), suggesting that the mTOR inhibitor has potent growth-inhibitory effects on sarcoma cells.

Discussion

PTEN has been widely characterised in a range of malignancies providing further elucidation on their pathogenesis and progression (24-26). Conversely, PTEN has not been comprehensively examined in sarcoma. This study provided greater insight into the PTEN status in a panel of 5 sarcoma cell lines from various soft tissue subtypes (liposarcoma, fibrosarcoma, synovial sarcoma and malignant fibrous histiocytoma) and demonstrated that PTEN dysfunction is uncommon in sarcoma cell lines (1/5). In addition, wild-type PTEN in 4 cell lines and mutated PTEN in the GCT cell line were unable to inhibit activated PI3K/mTOR/Akt signaling, highlighting the potential utility of targeting this pathway. Given the lack of effective targeted therapies in sarcoma, this study provided preclinical evidence demonstrating the effectiveness of the mTOR inhibitor, ridaforolimus, on sarcoma cell growth inhibition (IC₅₀<10 nM).

This study showed that PTEN mutation is rare in sarcoma cell lines and is not a major contributor to its dysfunction. Sequencing analysis revealed 1 out of the 5 cell lines, GCT, had
a biallelic missense mutation (C>T) in exon 6 of PTEN, which produces a change in the amino acid sequence from glycine to leucine (aa 204), and was associated with loss of PTEN protein expression. These findings are consistent with those of other studies, which have similarly shown PTEN gene alterations to be infrequent in sarcoma (27-29). For example, a study reported PTEN mutation was at a low rate of 2.3% in 86 STS tumour samples (30). Likewise, a separate study found a single PTEN mutation in only 1 of 40 samples of chondrosarcoma tumours (31). Further study of these infrequent mutations will be useful to identify alternative therapeutic strategies.

Sarcoma survival rates have reached a plateau in recent decades and there remains an urgent need to uncover novel targeted therapies to improve clinical outcomes (32, 33). Several deregulated signaling pathways in sarcoma have undergone intense study to develop effective drug inhibitors (34, 35). The
PI3K/AKT/mTOR pathway was shown to be up-regulated in the panel of sarcoma cell lines examined, with increased expression of phosphorylated Akt. These findings indicate that, despite a majority of the cell lines expressing the wild-type PTEN gene, they are unable to inhibit signal transduction in the PI3K pathway. This may be attributed to other aberrant signalling components, including gain-of-function mutations in the PIK3CA gene, leading to constitutive activation of the PI3K/AKT/mTOR cascade (36). mTOR serves as a central regulator of cell growth and division as part of the PI3K pathway (37). Specifically, it has an essential role in facilitating progression through the cell cycle and enabling cell proliferation. Therefore, mTOR inhibition with ridaforolimus is a promising therapeutic option to impede PI3K/AKT/mTOR signalling contributing to cell survival and has demonstrated effective growth inhibition in the panel of sarcoma cell lines. Moreover, several cell lines (HT1080 and SW982) exhibited profound sensitivity to this targeted agent, with IC50 below 1 nM. Likewise, multiple studies have demonstrated the potent antiproliferative effects of ridaforolimus and its ability to down-regulate the PI3K/AKT/mTOR pathway (38, 39). A study reported low nanomolar concentrations of ridaforolimus suppressed cellular proliferation of 11 sarcoma cell lines (40). In addition, ridaforolimus was able to block mTOR signaling, as evidenced by a reduction in phosphorylation of downstream effectors, 4E-BP1 and ribosomal protein S6. Collectively, these results demonstrate the usefulness of mTOR inhibition as a potential treatment option in sarcoma. Moving forward, the therapeutic efficacy of ridaforolimus needs to be verified in in vivo models. Additionally, functional analysis of PTEN in sarcoma cell lines and tissue samples is necessary to verify its tumour suppressor activity.

With over 70 different histological sarcoma subtypes, the panel of STS and osteosarcoma cell lines used in this study represents a small proportion of these tumours. Future studies should target a large cohort of patient samples comprising a wide range of sarcoma subtypes to validate in vitro results of PTEN status and therapeutic efficacy of targeted agents. In addition, further examination into detailed molecular mechanisms of inhibition and synergistic antitumour effects of combination therapy could be undertaken in prospective studies. Nonetheless, this study provided strong support for the ongoing investigation of ridaforolimus as a therapeutic agent in sarcoma.

Conclusion

In conclusion, this study demonstrated that the PTEN mutation is rare in the panel of sarcoma cell lines examined and constitutive activation of PI3K/Akt/mTOR pathway is independent of PTEN status. In addition, mTOR inhibition was shown to be an attractive monotherapeutic intervention with broad antiproliferative activity in sarcoma cell lines. Although the extrapolation of in vitro data to the clinical setting should be considered with caution, these results support the ongoing rational development of ridaforolimus and its analogues to obtain enhanced clinical outcomes in sarcoma treatment.

References


